Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

New studies question what we thought we knew about aspirin

Posted on December 17th, 2019 by in Chemistry

For decades, aspirin (acetylsalicylic acid) has been viewed as something of a wonder drug. A staple in most households, people have turned to it for everything from headache relief to heart attack prevention. However, recent studies have raised some serious questions about the benefits of regular aspirin usage.

(more…)

FDA collaborates with Elsevier on drug-induced liver injury (DILI) tool

Posted on December 3rd, 2019 by in Pharma R&D

A leading cause of attrition of compounds in drug development, drug-induced liver injury (DILI) is also one of the top causes of drug withdrawals, restrictions and project terminations. DILI results when reactive metabolites – formed when certain orally administered drugs are metabolized in the liver – end up binding to cellular proteins and damaging liver cells.

(more…)

Government Shutdown Means New Drugs May Have to Wait – But Safety Monitoring Will Continue

Posted on January 17th, 2019 by in Pharma R&D

The partial shutdown of the U.S. government, which began just before the Christmas holiday, has been especially terrible for hundreds of thousands of federal employees who are either furloughed or working without pay. (more…)

FDA Announces Plans to Improve Approvals Process for Medical Devices

Posted on January 15th, 2019 by in Pharma R&D

In the pharmaceutical industry, safety protocols are rigorous. Clinical trials, a lengthy and intense part of the drug development process, are deemed absolutely crucial to ensuring the safety and efficacy of new drugs and therapies. There are also many regulations designed to make certain that high standards are maintained during the various trial phases.

(more…)

  1. 1
  2. 2
  3. 3
  4. 7